J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.
Rachel A. Kudgus,Annamaria Szabolcs,Jameel Ahmad Khan,Chad A. Walden,Joel M. Reid,J. David Robertson,Resham Bhattacharya,Priyabrata Mukherjee +7 more
TL;DR: It is demonstrated in this study that the gold nanoparticle-based therapeutic containing gemcitabine inhibited tumor growth in an advanced stage of the disease in an orthotopic model of pancreatic cancer.
Journal ArticleDOI
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.
Joel M. Reid,Matthew P. Goetz,Sarah A. Buhrow,Chad A. Walden,Stephanie L. Safgren,Mary J. Kuffel,Kathryn E. Reinicke,Vera J. Suman,Paul Haluska,Xiaonan Hou,Matthew M. Ames +10 more
TL;DR: In murine models, oral ENDX yields substantially higher ENDX concentrations, compared to TAM, and these data support the ongoing development of ENDX as a novel agent for the endocrine treatment of ER-positive breast cancer.
Journal Article
Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A Children’s Oncology Group study
James A. Whitlock,Mark Krailo,Joel M. Reid,Stacie L. Ruben,Matthew M. Ames,William Owen,Gregory H. Reaman +6 more
TL;DR: The authors in this paper determined the dose-limiting toxicities (DLT), maximum tolerated dose (MTD) and pharmacokinetics of flavopiridol in children when administered as a one-hour infusion over three consecutive days.
Journal ArticleDOI
Flavone-8-Acetic Acid (Flavonoid) Profoundly Reduces Platelet-Dependent Thrombosis and Vasoconstriction After Deep Arterial Injury In Vivo
TL;DR: FAA markedly reduced platelet deposition, mural thrombi, and injury-induced vasoconstriction after deep arterial injury, suggesting that a major inhibition of platelet glycoprotein Ibalpha may be beneficial therapy.
Journal Article
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
Henry C. Pitot,Joel M. Reid,Jeff A. Sloan,Matthew M. Ames,Alex A. Adjei,Joseph Rubin,Pamela G. Bagniewski,Pamela J. Atherton,Daniel Rayson,Richard M. Goldberg,Charles Erlichman +10 more
TL;DR: Bizelesin administered every 4 weeks as an i.v. push is well tolerated with dose-limiting toxicity of neutropenia and the maximum-tolerated dose (and recommended Phase II dose) is 0.8 microg/m(2) administered onceevery 4 weeks.